Interferences With CGM Systems: Practical Relevance?
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Most systems for continuous glucose monitoring (CGM) are based on a specific electrochemical methodology for measuring glucose in interstitial subcutaneous fluid (ISF). The enzymes needed for the enzymatic reaction are located at the tip of the filaments that are inserted into the subcutaneous tissue using needles. However, depending on the particular enzyme chemistry and the voltage applied to measure the electron flow in relation to the glucose concentration in the ISF around the sensor tip, other substances can also influence the measurements taken by CGM systems, that is, shift the “glucose” data in one direction or the other. These interfering substances can be endogenous substances, as well as drugs or food components circulating in the human body. Despite the potential impact of interfering substances on CGM accuracy, there are few publications focusing on the interference of drugs and other substances on CGM system measurements.1-3 In addition, the CGM systems tested in these studies are mostly outdated. Manufacturers are required to perform interference studies during the clinical development process for each new CGM system and product generation to gain regulatory approval. However, the data generated by most of these studies are not published. Although interferences are well known and relevant when it comes to systems for self-measurement of blood glucose (SMBG), once again, publications are sparse.4 In this editorial, the publicly available information about interfering substances and how they influence glucose measurements from various CGM systems, manufactured by different companies, are summarized, with a focus on the clinical situation of people with diabetes (PwD). The subsequent summary is not comprehensive and will not cover all available CGM systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Medtronic Guardian 3, Medtronic Guardian 4 and Dexcom 6 are not recommended for people taking hydroxycarbamide (hydroxyurea), which can cause falsely elevated glucose readings.32”
From Blood glucose monitoring devices: current considerations (2023) · cites this paper as [32]
In the citing paper
“Hydroxyurea, used for myeloproliferative disorders and hematologic conditions, is one of the most recently identified interfering substances that cause a temporary increase in sensor glucose values discrepant from actual glucose values (129-134).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [129]
Citations
Cites
Vitamin C pharmacokinetics: Implications for oral and intravenous use
Padayatty, S. J., Sun, H., Wang, Y., Riordan, H. D., Hewitt, S. M., Katz, A., Wesley, R. A., & Levine, M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-7-200404060-00010 · Cited by 992
Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline
Galindo, R. J., Umpierrez, G. E., Rushakoff, R. J., Basu, A., Lohnes, S., Nichols, J. H., Spanakis, E. K., Espinoza, J., Palermo, N. E., Awadjie, D. G., et al. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820954163 · Cited by 170
Self-citationCerullo, G., Negro, M., Parimbelli, M., Pecoraro, M., Perna, S., Liguori, G., Rondanelli, M., Cena, H., & D’Antona, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574029 · Cited by 158
Effect of Acetaminophen on CGM Glucose in an Outpatient Setting
Maahs, D. M., DeSalvo, D., Pyle, L., Ly, T., Messer, L., Clinton, P., Westfall, E., Wadwa, R. P., & Buckingham, B. (2015) · Diabetes Care · doi:10.2337/dc15-1096 · Cited by 102
Basu, A., Veettil, S., Dyer, R. B., Peyser, T. A., & Basu, R. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0410 · Cited by 94
Plasma ascorbic acid: measurement, stability and clinical utility revisited
Chung, W. Y., Chung, J. K.-O., Szeto, Y. T., Tomlinson, B., & Benzie, I. F. F. (2001) · Clinical Biochemistry · doi:10.1016/s0009-9120(01)00270-3 · Cited by 89
Continuous Glucose Monitor Interference With Commonly Prescribed Medications: A Pilot Study
Basu, A., Slama, M. Q., Nicholson, W. T., Langman, L., Peyser, T., Carter, R., & Basu, R. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817697329 · Cited by 77
Heinemann, L. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0076 · Cited by 62
Self-citationResistance to Acetaminophen Interference in a Novel Continuous Glucose Monitoring System
Calhoun, P. M., Johnson, T. K., Hughes, J., Price, D. A., & Balo, A. K. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818755797 · Cited by 62
Vitamin C deficiency in dialysis patients--are we perceiving the tip of an iceberg?
Handelman, G. J. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl534 · Cited by 55
Research works printed but not linked: 1
- Schiavon M, 2018, Annu Int Conf IEEE Eng Med Biol Soc, 2018, 159
Cited by
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
Shaw, J. L. V., Bannuru, R. R., Beach, L. A., ElSayed, N. A., Freckmann, G., Füzéry, A. K., Fung, A. W. S., Gilbert, J. D., Yun, H., Korpi-Steiner, N. L., et al. (2024) · Diabetes Care · doi:10.2337/dci24-0073 · Cited by 77
Metadata
- Authors
- Heinemann, L.
- Affiliations
- Science-Consulting in Diabetes GmbH, Kaarst, Germany
- Corresponding author
- Heinemann, Lutz
- ORCID
- Heinemann, Lutz
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2021-12-15
- Volume
- 16
- Issue
- 2
- Pages
- 271-274
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC8861798
- OpenAlex
- W4200166937
- Cited by
- 65
- References
- 20
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 19 · 2023: 9 · 2022: 3
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Physical Sciences › Engineering › Biomedical Engineering › Wireless Body Area Networks
- Health Sciences › Medicine › Surgery › Healthcare Technology and Patient Monitoring
- Keywords
- continuous glucose monitoring, sensor interference, diabetes management
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Humans, Insulin Infusion Systems, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferences With CGM Systems: Practical Relevance? https://app.cochat.ai/papers/10.1177/19322968211065065
- The paper
- Heinemann, L. (2022). Interferences With CGM Systems: Practical Relevance? Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968211065065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.